Traders Buy High Volume of Merck & Co., Inc. Call Options (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) was the target of some unusual options trading on Friday. Stock traders purchased 170,441 call options on the company. This is an increase of 455% compared to the typical volume of 30,710 call options.

Merck & Co., Inc. Trading Down 1.4%

Shares of NYSE:MRK traded down $1.71 during midday trading on Friday, hitting $119.05. The company had a trading volume of 10,926,835 shares, compared to its average volume of 10,163,123. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $125.14. The firm has a fifty day simple moving average of $116.59 and a 200 day simple moving average of $113.19. The stock has a market cap of $294.04 billion, a price-to-earnings ratio of 33.54, a PEG ratio of 2.72 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the prior year, the company posted $2.22 earnings per share. The firm’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. Wells Fargo & Company reduced their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Citigroup initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target on the stock. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Friday, February 13th. Finally, Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $128.18.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. LFG Wealth Partners LLC increased its stake in Merck & Co., Inc. by 4.8% in the first quarter. LFG Wealth Partners LLC now owns 10,282 shares of the company’s stock valued at $1,237,000 after purchasing an additional 469 shares in the last quarter. Dakota Community Bank & Trust NA boosted its position in shares of Merck & Co., Inc. by 5.4% during the first quarter. Dakota Community Bank & Trust NA now owns 3,832 shares of the company’s stock worth $461,000 after purchasing an additional 197 shares in the last quarter. FAS Wealth Partners Inc. boosted its position in shares of Merck & Co., Inc. by 3.2% during the first quarter. FAS Wealth Partners Inc. now owns 40,727 shares of the company’s stock worth $4,899,000 after purchasing an additional 1,276 shares in the last quarter. Robinswood Financial LLC acquired a new position in shares of Merck & Co., Inc. in the 1st quarter valued at $127,000. Finally, Pine Valley Investments Ltd Liability Co increased its position in shares of Merck & Co., Inc. by 1.3% in the 1st quarter. Pine Valley Investments Ltd Liability Co now owns 54,101 shares of the company’s stock valued at $6,522,000 after buying an additional 701 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.